The FDA launched its regenerative medicine advanced therapy (RMAT) designation program, which stemmed from the 21st Century Cures Act, roughly one year ago. By now, at least 43 companies have applied for the new designation with more than a dozen recipients who can attest to the enhanced regulatory access and cooperation under the program.